Clinical Trials Browser

Phase 2 × Neuroblastoma × spartalizumab × Clear all

NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2 Recruiting

Neuroblastoma